{"id":"post-transplant-grazoprevir-and-elbasvir","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL3039533","moleculeType":"Small molecule","molecularWeight":"784.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Grazoprevir targets the HCV NS3/4A serine protease, which is essential for processing viral polyproteins. Elbasvir inhibits the NS5A protein, which is critical for viral RNA replication and assembly. Together, this combination directly blocks multiple steps of the HCV life cycle, achieving high cure rates in HCV-infected patients, including those in the post-transplant setting where standard treatments may be contraindicated or less effective.","oneSentence":"Grazoprevir and elbasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, preventing viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:42:14.365Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection in post-transplant patients (liver transplant recipients)"}]},"trialDetails":[{"nctId":"NCT02902120","phase":"PHASE4","title":"HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2017-05-01","conditions":"Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney","enrollment":21},{"nctId":"NCT04546802","phase":"PHASE3","title":"HepATocellular Cancer Hcv Therapy Study","status":"WITHDRAWN","sponsor":"Bayside Health","startDate":"2019-09","conditions":"Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma","enrollment":""},{"nctId":"NCT03249194","phase":"EARLY_PHASE1","title":"Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2017-08-17","conditions":"Kidney Transplant, Hepatitis C","enrollment":25},{"nctId":"NCT03359746","phase":"PHASE4","title":"Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant","status":"UNKNOWN","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2017-12-15","conditions":"Hepatitis C","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zepatier"],"phase":"marketed","status":"active","brandName":"Post-transplant Grazoprevir and Elbasvir","genericName":"Post-transplant Grazoprevir and Elbasvir","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Grazoprevir and elbasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, preventing viral replication. Used for Chronic hepatitis C virus infection in post-transplant patients (liver transplant recipients).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}